Early pancreatic cancer detection using an exosome microRNA blood test
Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic Cancer
A blood test that looks at tiny particles called exosomes and the microRNA they carry to spot pancreatic cancer early in people at risk.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11405536 on NIH RePORTER |
What this research studies
We collect a small blood sample and isolate exosomes—tiny particles released by cells—and read the microRNA they carry using genome-wide sequencing. Using bioinformatics and machine-learning, we combine signals from exosome microRNA and cell-free microRNA into a diagnostic signature that aims to detect early pancreatic tumors better than current markers like CA19-9. Earlier work by this team identified promising panels of microRNAs, and this project focuses on validating those markers in larger patient groups. The goal is to develop a reliable, non-invasive blood test that could be used during evaluation or screening of people at increased risk.
Who could benefit from this research
Good fit: Ideal candidates are adults at elevated risk for pancreatic cancer or people being evaluated for possible pancreatic disease, such as those with family history, genetic risk factors, chronic pancreatitis, new-onset diabetes, or unexplained symptoms.
Not a fit: People already diagnosed with advanced pancreatic cancer or those whose tumors do not release the specific exosome/microRNA signature may not receive direct benefit from this test.
Why it matters
Potential benefit: If successful, this could enable non-invasive, earlier detection of pancreatic cancer so people can start treatment sooner and have a better chance of improved outcomes.
How similar studies have performed: Prior work by the investigators identified small panels of circulating and exosome microRNAs that could distinguish early-stage pancreatic cancer, but broader validation in larger cohorts is still needed.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Goel, Ajay — Beckman Research Institute/city of Hope
- Study coordinator: Goel, Ajay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.